Skip to main content

. 1991 Apr 20;302(6782):970. doi: 10.1136/bmj.302.6782.970

Allergy to spiramycin during prophylactic treatment of fetal toxoplasmosis.

L S Ostlere ¹, J A Langtry ¹, R C Staughton ¹

PMCID: PMC1669460 PMID: 2032060

970

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Daffos F., Forestier F., Capella-Pavlovsky M., Thulliez P., Aufrant C., Valenti D., Cox W. L. Prenatal management of 746 pregnancies at risk for congenital toxoplasmosis. N Engl J Med. 1988 Feb 4;318(5):271–275. doi: 10.1056/NEJM198802043180502. [DOI] [PubMed] [Google Scholar]
Descotes J., Vial T., Delattre D., Evreux J. C. Spiramycin: safety in man. J Antimicrob Chemother. 1988 Jul;22 (Suppl B):207–210. doi: 10.1093/jac/22.supplement_b.207. [DOI] [PubMed] [Google Scholar]
Desmonts G., Couvreur J. Congenital toxoplasmosis. A prospective study of 378 pregnancies. N Engl J Med. 1974 May 16;290(20):1110–1116. doi: 10.1056/NEJM197405162902003. [DOI] [PubMed] [Google Scholar]
Galland M. C., Rodor F., Jouglard J. Toxidermie évoquant une vascularite allergique et spiramycine. Therapie. 1987 Mar-Apr;42(2):227–229. [PubMed] [Google Scholar]
Hohlfeld P., Daffos F., Thulliez P., Aufrant C., Couvreur J., MacAleese J., Descombey D., Forestier F. Fetal toxoplasmosis: outcome of pregnancy and infant follow-up after in utero treatment. J Pediatr. 1989 Nov;115(5 Pt 1):765–769. doi: 10.1016/s0022-3476(89)80660-2. [DOI] [PubMed] [Google Scholar]

ACTIONS

RESOURCES